New Enzyme Structures Could Improve Cannabinoid Production

For decades, scientists have known that cannabis relies on a handful of specialized enzymes to transform a single precursor into some of the plant’s most valuable cannabinoids. What has remained far less clear is why nearly identical enzymes produce dramatically different compounds. An emerging study¹ may finally provide that missing piece of the puzzle, offering detailed molecular blueprints that could reshape how cannabinoids are manufactured in the future.

Rather than focusing on breeding new cannabis varieties or extracting compounds from plants, the research examined the three enzymes responsible for converting CBGA into CBCA, CBDA, or THCA. By determining their three-dimensional crystal structures, researchers uncovered subtle structural differences that help explain why each enzyme consistently produces a different cannabinoid.

The findings could have important implications for pharmaceutical manufacturing, synthetic biology, and fermentation-based cannabinoid production, where greater precision may eventually allow manufacturers to produce desired cannabinoids while minimizing unwanted byproducts.

Why CBGA Is So Important

Nearly every major cannabinoid found in cannabis begins with CBGA, often called the “mother cannabinoid.” This molecule serves as the starting material for several cannabinoid synthase enzymes. Each synthase performs a remarkably similar chemical reaction, yet the end products differ substantially.

While each enzyme accepts CBGA, subtle active site differences dictate their primary output and side-product tendencies:

After harvest or heating, these acidic cannabinoids become the familiar compounds CBC, CBD, and THC through decarboxylation. Although these enzymes share a high degree of genetic similarity, they consistently favor different products. Until now, scientists only had a crystal structure for THCA synthase, leaving important questions about the structural basis of cannabinoid selectivity unanswered.

Researchers Solved Three Enzyme Structures

To better understand these enzymes, the researchers produced CBCAS, CBDAS, and THCAS using the yeast Komagataella phaffii. After purifying each enzyme through multiple laboratory techniques, they determined high-resolution X-ray crystal structures for all three enzymes while bound to their flavin adenine dinucleotide (FAD) cofactor. Having all three structures available allows researchers to directly compare enzymes that perform nearly identical chemistry but generate different cannabinoid products.

The comparison revealed that cannabinoid synthases are remarkably alike overall. However, small differences within and around the regions where chemical reactions occur appear to influence which cannabinoid ultimately forms.

Some of these differences involve amino acids that directly contact the substrate, while others occur farther away but subtly alter the shape of the enzyme or affect how CBGA enters the active site. Together, these seemingly minor structural variations help explain the enzymes’ distinct chemical preferences.

Small Structural Changes Matter

One of the study’s most important findings is that cannabinoid synthase selectivity is controlled by extremely subtle structural features rather than dramatic architectural differences. The researchers identified both direct amino acid substitutions within the active site and more distant changes that indirectly reshape the catalytic environment. These remote structural effects influence the topology of the active site and may alter substrate positioning or accessibility, ultimately steering the reaction toward CBCA, CBDA, or THCA.

Understanding these relationships is significant because it provides scientists with a detailed molecular map of how cannabinoid synthases function instead of relying solely on trial-and-error experimentation. This type of structural knowledge makes it possible to predict how changing individual amino acids could alter enzyme behavior.

Better Enzymes for Cannabinoid Production

Perhaps the most commercially important aspect of the study is what these structures enable next. The researchers conclude that the structural data provide a platform for the rational engineering of cannabinoid synthases with improved or altered chemical selectivity. Rather than randomly modifying enzymes and testing thousands of variants, scientists can now make targeted changes based on the enzyme’s three-dimensional structure. This approach could support the development of enzyme systems that produce desired cannabinoids more efficiently while generating fewer unwanted side products.

One example highlighted by the researchers involves CBDA production. Current biosynthetic methods can sometimes generate small amounts of THCA alongside CBDA because of imperfect enzyme selectivity. Although these quantities may be minor, even trace THC contamination can create regulatory and manufacturing challenges depending on the intended product and jurisdiction. Engineering CBDAS to eliminate or greatly reduce this unwanted THCA production could improve manufacturing consistency while simplifying downstream purification.

Implications for Synthetic Biology

The research also supports growing interest in producing cannabinoids without cultivating cannabis plants. In recent years, scientists have explored engineering yeast and other microorganisms to manufacture cannabinoids through fermentation. This approach has the potential to provide consistent production conditions, reduce agricultural variability, and simplify the manufacture of pharmaceutical-grade cannabinoids.

However, the success of these systems depends heavily on the enzymes driving cannabinoid biosynthesis. If synthases produce unwanted compounds alongside the target cannabinoid, manufacturers must invest additional time and resources into purification. More selective enzymes could improve production efficiency while reducing waste and increasing overall process control.

The newly solved crystal structures provide valuable design information for scientists developing these next-generation biosynthetic platforms.

Benefits for Pharmaceutical Development

Highly selective cannabinoid production could become increasingly valuable as cannabinoid-based medicines continue to expand. Pharmaceutical manufacturers typically require products with precise chemical compositions and consistent purity from batch to batch. Even small variations in cannabinoid profiles may complicate quality control or regulatory approval.

By enabling more precise enzyme engineering, the new structural information may eventually support manufacturing methods capable of producing cannabinoids with greater consistency and fewer contaminants. Although additional research will be necessary before engineered enzymes reach commercial production, structural biology represents an important foundation for these future advances.

What the Study Does Not Show

While the findings are scientifically important, the study does not demonstrate a new method for producing cannabinoids at industrial scale. Instead, the research provides detailed structural information that can guide future enzyme engineering efforts. The authors describe the crystal structures as a platform for rational design rather than evidence that improved synthases have already been created.

Likewise, the study does not suggest changes to cannabinoid safety or effectiveness. Its primary contribution is explaining why these closely related enzymes generate different cannabinoid products and providing researchers with the information needed to potentially redesign them.

A Blueprint for Future Cannabinoid Engineering

Cannabinoid science increasingly extends beyond studying the cannabis plant itself. Advances in structural biology, protein engineering, and synthetic biology are opening new possibilities for producing cannabinoids with greater precision than traditional cultivation alone.

By revealing the molecular structures of CBCAS, CBDAS, and THCAS, this study fills a longstanding gap in researchers’ understanding of cannabinoid biosynthesis. More importantly, it offers a practical blueprint for engineering enzymes that may one day manufacture specific cannabinoids more efficiently, with greater purity, and with fewer unwanted byproducts.

While consumers are unlikely to notice the effects immediately, these structural discoveries could eventually influence how pharmaceutical cannabinoids and fermentation-derived cannabinoid ingredients are produced, helping make future manufacturing cleaner, more controllable, and better suited to the growing demands of medical and research applications.

References:

^{1. Domenech, J., King, A., Byrne, E., Cartwright, J., Grogan, G., X-ray crystal structures of the cannabinoid synthases CBCAS, CBDAS and THCAS, Current Research in Structural Biology, https://doi.org/10.1016/j.crstbi.2026.100197}